Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy

Journal of Infectious Diseases

Volumn 215, Issue 11, 2017, Pages 1725-1733

  Gay, Cynthia L ^a   Bosch, Ronald J ^b   Ritz, Justin ^b   Hataye, Jason M ^c   Aga, Evgenia ^b   Tressler, Randall L ^d,e   Mason, Stephen W ^f,j   Hwang, Carey K ^f,k   Grasela, Dennis M ^f   Ray, Neelanjana ^f   Cyktor, Josh C ^g   Coffin, John M ^h   Acosta, Edward P ⁱ   Koup, Richard A ^c   Mellors, John W ^g   Eron, Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Vaccine Research Center   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Columbus Technologies ^*  (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^j SWM Consulting   (United Kingdom)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Anti PD L1; BMS 936559; Checkpoint inhibitors; HIV cure; HIV eradication; Human immunodeficiency virus type 1 (HIV 1); Immune response

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BMS 936559; CD4 ANTIGEN; CD8 ANTIGEN; CREATINE KINASE; GAG PROTEIN; GAMMA INTERFERON; PLACEBO; VIRUS RNA; ANTIRETROVIRUS AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ARTICLE; BLURRED VISION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHEST TIGHTNESS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG SAFETY; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOGONADISM; HYPOPHYSITIS; INJURY; LEG PAIN; LOW DRUG DOSE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED;

EID: 85028448586     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix191     Document Type: Article

References (37)

1. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879-84.
2. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202.
3. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 2281-92.
4. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37.
5. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-9.
6. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-13.
7. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-4.
8. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIVspecific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8: 1246-54.
9. Meier A, Bagchi A, Sidhu HK, et al. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 2008; 22: 655-8.
10. Boasso A, Hardy AW, Landay AL, et al. PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol 2008; 129: 132-44.
11. Hoffmann M, Pantazis N, Martin GE, et al.; SPARTAC and CHERUB Investigators. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS Pathog 2016; 12: e1005661.
12. D'Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T-cell dysfunction. J Immunol 2007; 179: 1979-87.
13. Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr 2010; 54: 447-54.
14. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011; 11: 43.
15. Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101: 2514-20.
16. Rosignoli G, Cranage A, Burton C, et al. Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS 2007; 21: 1379-81.
17. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-3.
18. Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebocontrolled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013; 8: e63818.
19. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014; 10: e1003856.
20. Mason SW, Sanisetty S, Osuna-Gutierrez C, et al. Viral suppression was induced by anti-PD-L1 following ARV-interruption in SIV-infected monkeys [abstract 318LB]. In: Program and abstracts of the 2014 Conference on Retroviruses and Opportunistic Infections. Boston, MA: CROI, 2014.
21. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-10.
22. Dyavar Shetty R, Velu V, Titanji K, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122: 1712-6.
23. Palmer BE, Neff CP, Lecureux J, et al. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol 2013; 190: 211-9.
24. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
25. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
26. La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 2015; 35: 963-76.
27. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-48.
28. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 2016; 11: e0160221.
29. Cillo AR, Vagratian D, Bedison MA, et al. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 2014; 52: 3944-51.
30. Hong F, Aga E, Cillo AR, et al. Novel assays for measurement of total cellassociated HIV-1 DNA and RNA. J Clin Microbiol 2016; 54: 902-11.
31. Liang M, Schwickart M, Schneider AK, et al. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom 2016; 90: 117-27.
32. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781-9.
33. Gill AL, Green SA, Abdullah S, et al. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). AIDS 2016; 30: 2487-93.
34. George MM, Bhangoo A. Human immune deficiency virus (HIV) infection and the hypothalamic pituitary adrenal axis. Rev Endocr Metab Disord 2013; 14: 105-12.
35. Lachâtre M, Pasquet A, Ajana F, et al. HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy. AIDS 2017; 31: 451-3.
36. Gomes AR, Souteiro P, Silva CG, et al. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. BMC Infect Dis 2016; 16: 628.
37. González-Rodríguez E, Rodríguez-Abreu D; Spanish Group for Cancer Immuno- Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 2016; 21: 804-16.